A phase 1 study to evaluate the safety and immunogenicity of a recombinant HIV type 1 subtype C-modified vaccinia ankara virus vaccine candidate in Indian volunteers

AIDS Research and Human Retroviruses

Volumn 25, Issue 11, 2009, Pages 1107-1116

  Ramanathan, Vadakkuppatu Devasenapathi ^a   Kumar, Makesh ^a   Mahalingam, Jayashri ^a   Sathyamoorthy, Pattabiraman ^a   Narayanan, Paranji Ramaiyengar ^a   Solomon, Suniti ^b   Panicali, Dennis ^c   Chakrabarty, Sekhar ^d   Cox, Josephine ^e   Sayeed, Eddy ^e   Ackland, James ^e   Verlinde, Carl ^e   Vooijs, Dani ^e   Loughran, Kelley ^f   Barin, Burc ^f   Lombardo, Angela ^e   Gilmour, Jill ^g   Stevens, Gwynneth ^f   Smith, Michelle Seth ^d   Tarragona Fiol, Tony ^d   Hayes, Peter ^d   Kochhar, Sonali ^d   Excler, Jean Louis ^e   Fast, Patricia ^e   more..

^a NATIONAL INSTITUTE FOR RESEARCH IN TUBERCULOSIS   (India)

^b YRG CARE   (India)

^c National Institute of Cholera and Enteric Diseases ^*

^d INTERNATIONAL AIDS VACCINE INITIATIVE   (United States)

^e EMMES CORPORATION   (United States)

^f IMPERIAL COLLEGE LONDON   (United Kingdom)

^g IAVI Southern Africa   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GAG PROTEIN; GAMMA INTERFERON; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; MODIFIED VACCINIA VIRUS ANKARA VACCINE; PLACEBO; UNCLASSIFIED DRUG; VACCINIA VACCINE; VIRUS ENVELOPE PROTEIN;

ADULT; ARTHRALGIA; ARTICLE; CHILL; CLINICAL ARTICLE; CLINICAL TRIAL; CONCUSSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG SAFETY; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME LINKED IMMUNOSPOT ASSAY; ERYTHEMA; FATIGUE; FEMALE; FEVER; HEAD INJURY; HEADACHE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IMMUNE RESPONSE; IMMUNOGENICITY; INDIAN; LOW BACK PAIN; MALAISE; MALE; MYALGIA; NERVE COMPRESSION; PAIN; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; SKIN DISCOLORATION; SKIN INDURATION; SKIN MANIFESTATION; SKIN SWELLING; SPONDYLOLISTHESIS; SPONDYLOSIS; TREATMENT DURATION; URETER STONE; VACCINATION; VOMITING;

ADOLESCENT; ADULT; AIDS VACCINES; DOUBLE-BLIND METHOD; FEMALE; HIV ANTIBODIES; HIV INFECTIONS; HIV-1; HUMAN IMMUNODEFICIENCY VIRUS PROTEINS; HUMANS; INDIA; INTERFERON-GAMMA; MALE; MIDDLE AGED; TREATMENT OUTCOME; VACCINES, DNA; VACCINIA VIRUS; YOUNG ADULT;

EID: 71949091412     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/aid.2009.0096     Document Type: Article

References (49)

1. UNAIDS: AIDS epidemic update, December 2007.
2. Mehendale SM, Shepherd ME, Divekar AD, et al.: Evidence for high prevalence and rapid transmission of HIV among individuals attending STD clinics in Pune, India. Indian J Med Res 1996;104:327-335.
3. Gangakhedkar RR, Bentley ME, Divekar AD, et al.: Spread of HIV infection in married monogamous women in India. JAMA 1997;278:2090-2092.
4. Bollinger RC, Brookmeyer RS, Mehendale SM, et al.: Risk factors and clinical presentation of acute primary HIV infection in India. JAMA 1997;278:2085-2089.
5. Khan IF, Vajpayee M, Prasad VV, and Seth P: Genetic diversity of HIV type 1 subtype C env gene sequences from India. AIDS Res Hum Retroviruses 2007;23:934-940.
6. Sahni AK, Prasad VV, and Seth P: Genomic diversity of human immunodeficiency virus type-1 in India. Int J STD AIDS 2002;13:115-118.
7. Lakhashe S, Tripathy S, Paranjape R, and Bhattacharya J: Characterization of B=C recombinants of near full-length HIV type 1 from northeastern India with mosaics identical to ARE195FL but with a different ancestral origin. AIDS Res Hum Retroviruses 2008;24:92-99.
8. Walker B and Burton DR: Toward an AIDS vaccine. Science 2008;320:760-764.
9. Gupta SB, Jacobson LP, Margolick JB, et al.: Estimating the benefit of an HIV-1 vaccine that reduces viral load set point. J Infect Dis 2007;4:546-550.
10. Berkley SF and Koff WC: Scientific and policy challenges to development of an AIDS vaccine. Lancet 2007;370:94-101.
11. Hanke T, McMichael AJ, Dennis MJ, et al.: Biodistribution and persistence of an MVA-vectored candidate HIV vaccine in SIV-infected rhesus macaques and SCID mice. Vaccine 2005;23:1507-1514.
12. Frey SE, Newman FK, Kennedy JS, et al.: Clinical and immunologic responses to multiple doses of IMVAMUNE (modified vaccinia Ankara) followed by Dryvax challenge. Vaccine 2007;25:8562-8573.
13. Hanke T, McMichael AJ, and Dorrell L: Clinical experience with plasmid DNA- and modified vaccinia virus Ankaravectored human immunodeficiency virus type 1 clade A vaccine focusing on T-cell induction. J Gen Virol 2007;88 (Pt. 1):1-12.
14. Cebere I, Dorrell L, McShane H, et al.: Phase I clinical trial safety of DNA- and modified virus Ankara-vectored human immunodeficiency virus type 1 (HIV-1) vaccines administered alone and in a prime-boost regime to healthy HIV-1- uninfected volunteers. Vaccine 2006;4:417-425.
15. Smith JM, Amara RR, McClure HM, et al.: Multiprotein HIV type 1 clade B DNA=MVA vaccine: Construction, safety, and immunogenicity in macaques. AIDS Res Hum Retroviruses 2004;6:654-665.
16. Sandstrom E, Nilsson C, Hejdeman B, et al.: Broad immunogenicity of a multigene, multiclade HIV-1 DNA vaccine boosted with heterologous HIV-1 recombinant modified vaccinia virus Ankara. J Infect Dis 2008;198:1482-1490.
17. Ho DD: Construction, development, and evaluation of matched clade-C=B+ DNA- and MVA-based HIV-1 vaccine candidates. AIDS Vaccine 2006 Conference, Amsterdam, the Netherlands, 29 August-1 September 2006 (Abstract S07-05).
18. Cosma A, Nagaraj R, Buhler S, et al.: Therapeutic vaccination with MVA-HIV-1 nef elicits Nef-specific T-helper cell responses in chronically HIV-1 infected individuals. Vaccine 2003;22:21-29.
19. Dunachie SJ, Walther M, Epstein JE, et al.: A DNA primemodified vaccinia virus Ankara boost vaccine encoding thrombospondin-related adhesion protein but not circumsporozoite protein partially protects healthy malaria-naive adults against Plasmodium falciparum sporozoite challenge. Infect Immun 2006;10:5933-5942.
20. Pathan AA, Sander CR, Fletcher HA, et al.: Boosting BCG with recombinant modified vaccinia Ankara expressing antigen 85A: Different boosting intervals and implications for efficacy trials. PLoS ONE 2007;2:e1052.
21. Harrop R, John J, and Carroll MW: Recombinant viral vectors: Cancer vaccines. Adv Drug Deliv Rev 2006;8:931-947. (Pubitemid 44709263)
22. Excler JL, Kochhar S, Kapoor S, et al.: Preparedness for AIDS vaccine trials in India. Indian J Med Res 2008;127:531-538.
23. Goonetilleke N, Moore S, Dally L, et al.: Induction of multifunctional human immunodeficiency virus type 1 (HIV-1)- specific T cells capable of proliferation in healthy subjects by using a prime-boost regimen of DNA- and modified vaccinia virus Ankara-vectored vaccines expressing HIV-1 Gag coupled to CD8+ T-cell epitopes. J Virol 2006;80:4717-4728.
24. Petropoulos CJ, Parkin NT, Limoli KL, et al.: A novel phenotypic drug susceptibility assay for human immunodeficiency virus type 1. Antimicrob Agents Chemother 2000;44: 920-928
25. Selvarajah S, Puffer BA, Lee FH, et al.: Focused dampening of antibody response to the immunodominant variable loops by engineered soluble gp140. AIDS Res Hum Retroviruses 2008;24:301-314.
26. Excler JL and Plotkin S: The prime-boost concept applied to HIV preventive vaccines. AIDS 1997;11(Suppl. A):S127-137.
27. Fast PE: Recent trends in clinical trials of vaccines to prevent HIV=AIDS. Curr Opin HIV AIDS 2006;1:267-271.
28. Belyakov IM, Ahlers JD, Nabel GJ, Moss B, and Berzofsky JA: Generation of functionally active HIV-1 specific CD8+CTL in intestinal mucosa following mucosal, systemic or mixed prime-boost immunization. Virology 2008;381:106-115.
29. Van Rompay KK, Greenier JL, Cole KS, et al.: Immunization of newborn rhesus macaques with simian immunodeficiency virus (SIV) vaccines prolongs survival after oral challenge with virulent SIVmac251. J Virol 2003;77:179-190.
30. Watkins DI, Burton DR, Kallas EG, Moore JP, and Koff WC: Nonhuman primate models and the failure of the Merck HIV-1 vaccine in humans. Nat Med 2008;14:617-621.
31. Mehendale S, van Lunzen J, Clumeck N, et al.: A phase 1 study to evaluate the safety and immunogenicity of a recombinant HIV type 1 subtype C adeno-associated virus vaccine. AIDS Res Hum Retroviruses 2008;24:873-880.
32. Cassimatis DC, Atwood JE, Engler RM, Linz P, Grabenstein JD, and Vernalis MN: Smallpox vaccination and myopericarditis: A clinical review. J Am Coll Cardiol 2004;43:1503-1510.
33. Eckart RE, Lowe, SS, Atwood JE, et al.: Incidence and followup of inflammatory cardiac complications after smallpox vaccination. J Am Coll Cardiol 2004;44:201-205.
34. Bart PA, Goodall R, Barber T, et al.: EV01: A phase I trial in healthy HIV negative volunteers to evaluate a clade C HIV vaccine, NYVAC-C undertaken by the EuroVacc Consortium. Vaccine 2008;26:3153-3161.
35. McCormack S, Stohr W, Barber T, Bart PA, Harari A, and Moog C: EV02: A phase I trial to compare the safety and immunogenicity of HIV DNA-C prime-NYVAC-C boost to NYVAC-C alone. Vaccine 2008;26:3162-3174.
36. Parrino J, McCurdy LH, Larkin BD, et al.: Safety, immunogenicity and efficacy of modified vaccinia Ankara (MVA) against Dryvax- challenge in vaccinia-naive and vacciniaimmune individuals. Vaccine 2007;25:1513-1525.
37. Koff WC, Johnson PR, Watkins DI, et al.: HIV vaccine design: Insights from live attenuated SIV vaccines. Nat Immunol 2006;7:19-23.
38. Goepfert PA, Lumm W, Farmer P, et al.: Transmission of HIV-1 Gag immune escape mutations is associated with reduced viral load in linked recipients. J Exp Med 2008;205: 1009-1017.
39. Allen TM and Altfeld M: Crippling HIV one mutation at a time. J Exp Med 2008;205:1003-1007.
40. Peters BS, Jaoko W, Vardas E, et al.: Studies of a prophylactic HIV-1 vaccine candidate based on modified vaccinia virus Ankara (MVA) with and without DNA priming: Effects of dosage and route on safety and immunogenicity. Vaccine 2007;25:2120-2127.
41. Priddy FH, Brown D, Kublin J, et al.: Safety and immunogenicity of a replication-incompetent adenovirus type 5 HIV-1 clade B gag=pol=nef vaccine in healthy adults. Clin Infect Dis 2008;46:1769-1781.
42. Catanzaro AT, Koup RA, Roederer M, et al.: Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 candidate vaccine delivered by a replication-defective recombinant adenovirus vector. J Infect Dis 2006;194:1638-1649.
43. Spearman P: HIV vaccine development: Lessons from the past and promise for the future. Curr HIV Res 2003;1:101-120.
44. Catanzaro AT, Roederer M, Koup RA, et al.: Phase I clinical evaluation of a six-plasmid multiclade HIV-1 DNA candidate vaccine. Vaccine 2007;25:4085-4092.
45. Harari A, Bart PA, Stohr W, et al.: An HIV-1 clade C DNA prime, NYVAC boost vaccine regimen induces reliable, polyfunctional, and long-lasting T cell responses. J Exp Med 2008;205:63-77.
46. Dubey S, Clair J, Fu TM, et al.: Detection of HIV vaccineinduced cell-mediated immunity in HIV-seronegative clinical trial participants using an optimized and validated enzyme-linked immunospot assay. J Acquir Immune Defic Syndr 2007;45:20-27.
47. Moodie Z, Huang Y, Gu L, Hural J, and Self SG: Statistical positivity criteria for the analysis of ELISpot assay data in HIV-1 vaccine trials. J Immunol Methods 2006;315:121-132.
48. Lin J, Calcedo R, Vandenberghe LH, Figueredo JM, and Wilson JM: Impact of preexisting vector immunity on the efficacy of adeno-associated virus-based HIV-1 Gag vaccines. Hum Gene Ther 2008;19:663-669.
49. Sharpe S, Polyanskaya N, Dennis M, et al.: Induction of simian immunodeficiency virus (SIV)-specific CTL in rhesus macaques by vaccination with modified vaccinia virus Ankara expressing SIV transgenes: Influence of pre-existing anti-vector immunity. J Gen Virol 2001;82:2215-2223.